BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 9, Issue 2
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (10955)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.
Item 
Count 
PDF765
WORD369
HTML5937
Figures (1-2)519
Tables (1-1)585
 Sum=8175
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1256
Download1524
 Sum=2780
Jan 18, 2017 (publication date) through Oct 23, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
Copyright ©The Author(s) 2017.
World J Hepatol. Jan 18, 2017; 9(2): 80-90
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.80
Table 1 Randomized Phase III trials in advanced hepatocellular carcinoma
Drugn (patients)OS (mo)HR
SOR/Exp arm
First line completed (Sorafenib standard)
Brivanib11559.9/9.51.06
Sunitinib107410.2/7.91.3
Sorafenib/Erlotinib7208.5/9.50.92
Linifanib10359.8/9.11.04
Second line completed (placebo standard)
Brivanib3958.2/9.40.89
Everolimus5467.3/7.61.05
Ramucirumab5657.6/9.20.86
OS: Overall survival; SOR: Sorafenib arm.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345